Navigation Links
MetaStat, Inc. Executes Two New Licenses
Date:4/27/2012

of anti-metastatic drugs. There are currently no FDA approved drugs to target and kill these metastatic cells.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. We believe this is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were difficult because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

"Human Invasion Signature for Prognosis of Metastatic Risk," another result of our proprietary ability to isolate metastatic cells, describes the actual causative gene signature of metastatic cells. This approach contrasts with currently available technology that purports to evaluate risk of cancer recurrence by relying upon correlative mathematical algorithms developed through the statistical analysis of whole tumor tissue samples.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast is expected to be an important guide to treatment strategies for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying thi
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc.
2. MetaStat, Inc. Completes Share Exchange with PhotoVoltaic Solar Cells, Inc.
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
9. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
10. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... Reportlinker.com announces that a new market research ... Macular Degeneration Therapy Area Pipeline Report ... Macular Degeneration Therapy Area Pipeline Report contains detailed ... report provides insight into the pipeline status of ...
... April 13, 2011 Allscripts (NASDAQ: MDRX ) ... the three months ended March 31, 2011 after the stock ... host a conference call and webcast to discuss the company,s ... on the same day. (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:2/27/2015)... Daytona Beach, FL (PRWEB) February 27, 2015 ... marketing medical companies, devices and pharmaceuticals, Benedict Advertising ... FL as its newest client. The company’s patented ... is a pain-free, no-stress method of sedation. , ... taking medical patient comfort to a new level, ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 The winter ... mold growth and expansion. When mold grows, it can be ... be sure to avoid the consequences of mold growth with ... Long Island, is offering tips on the best ways to ... wet season, which makes perfect conditions for mold to thrive. ...
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized ... Plus hospital. In order to receive the award, Florida ... all Get With The Guidelines - Stroke Quality Achievement ... achieved 75-percent or higher compliance with six of 10 ... are reporting initiatives to measure quality of care. ...
(Date:2/27/2015)... The UC Davis Huntington’s Disease Center, whose ... a beacon of hope for people with Huntington’s disease ... the national society committed to the values that it ... America — as a Level 1 Huntington’s Disease Center ... service to over 300 families coping with Huntington's disease ...
Breaking Medicine News(10 mins):Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... ... and other patient safety information in the public eye , ... San Francisco vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Dallas/Fort Worth area vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... , Feb. 2 It,s all smiles in Waterbury ... Wolcott Street, Waterbury, CT in the Fair Oaks Shopping Center. ... January 22nd, 2010 in a mission to expand access to ...  Senator J. Hartley and State Representative Selim Noujaim joined the ...
... ... at CoastToCoastMattress.com. Featuring star name brands like Sealy Posturepedic, Simmons Beautyrest and Tempur-Pedic, the ... , ... 2010 -- Coast To Coast Mattress is proud to announce its new mattress lineup, ...
... , ... partnership with SLI-Systems brings advanced Learning Search & Navigation to online health & beauty ... (PRWEB) ... functionality across the Medichest.com platform. , , , , ,Learning Search tracks and ...
... ... the new Wella SP range is set to raise the bar within the hair ... Newport Pagnell, ... world, Wella is at the forefront of hairdressing innovation. The introduction of New SP personalised ...
Cached Medicine News:Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 2Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 3Health News:Coast To Coast Mattress Announces Its New Mattress Lineup 2Health News:Medichest Launches Learning Search 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: